Full-Time

Ocular Surgery Account Manager

Harrow

Harrow

201-500 employees

Compounds ophthalmic formulations; markets branded drugs

No salary listed

Chicago, IL, USA

Remote

Category
Sales & Account Management (1)
Requirements
  • Bachelor’s degree in a related field
  • Has 3+ years of successful ophthalmology sales experience with buy and bill sales and/or ophthalmic medical device sales experience preferred
  • Ability to build, develop, and foster longstanding relationships with customers
  • Ability to quickly absorb product and practice information and offer solutions that resonate
  • Experience with the execution of strategic and targeted business plans around priorities and goals
  • Proficient with MS Office products, including Word, Excel, and PowerPoint
  • Knowledge of how physicians make decisions regarding patient care for various therapies
  • Excellent presentation and interpersonal skills
  • Solid independent judgment and initiative required
  • Superior communication and written skills are a must
  • Ability to multitask, adjusting priorities as needed
  • Good problem-solving and analytical skills
  • Ability to become proficient with Salesforce CRM
  • Remote position
  • Travel expected about 100% in field with overnight stays
Responsibilities
  • Takes 100% ownership, with an entrepreneurial mindset, to meet or exceed quarterly sales revenue and product goals
  • Ability to effectively communicate complex clinical information to ophthalmic surgeons, billers, and administration in both the surgeon’s office and ASC
  • Adept understanding of complex care systems and strong capability to assess local dynamics to inform area business growth acceleration plans
  • Solid understanding of reimbursement concepts as they relate to buy and bill
  • Develop critical physician and ASC staff relationships within the assigned geography
  • Utilizes all internal resources when developing quarterly action plans or handling problem accounts
  • Provides weekly new business forecasts and updates
  • All sales activity is adequately recorded in CRM
  • Maintain an in-depth and professional level understanding of the Harrow surgical peri-operative products
  • Collaborate effectively with internal departments and peers
  • Act with a sense of urgency at all levels of customer care and follow up
  • Ability to travel throughout the assigned geography on a routine basis
  • Utilize the designated CRM system – Salesforce
  • Understand and follow all industry and company policies and guidelines
  • Comply with all state and federal legislation and regulatory requirements
  • Manage expenses in a thoughtful, responsible, and ethical manner
  • Resourceful thinker that may not have a complete roadmap to success, but finds the resources available to win and prosper
  • Acts as the liaison for customer complaints or issues with continual follow-up
  • Submits all required reports, including monthly expense reports, on time
Desired Qualifications
  • Experience with the expansion of business with ophthalmology surgical products
  • Knowledge of ophthalmic peri-operative products
  • Experience in remote selling behaviors
  • Familiarity with retina portfolio products and TRIESENCE or other peri-operative products

Harrow focuses on eyecare pharmaceuticals, combining a compounding business (ImprimisRx) with a portfolio of FDA-approved branded drugs and biosimilars, plus biotech investments. Its products include customized compounded sterile and topical eye medications delivered directly to physicians and patients, alongside branded drugs acquired from other companies. The company differentiates itself by integrating a direct-to-physician compounding platform with an expanding branded drug portfolio, biosimilars, and owned production and distribution facilities across all 50 states. Its goal is to provide accessible, high-quality eye medications and grow its commercial and biotech assets to serve surgeons, hospitals, and patients nationwide.

Company Size

201-500

Company Stage

IPO

Headquarters

Nashville, Tennessee

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • VEVYE reached 14% market share with 25% sequential prescription growth in Q1 2026.
  • TRIESENCE unit volume surged 136% year-over-year; BYOOVIZ and IOPIDINE J-code launches in H2 2026.
  • Doubled sales force and $250M debt raise fund aggressive commercial expansion through 2026.

What critics are saying

  • Nordic Pharma authorized generic Maxitrol launch April 2025 erodes $20.8M branded pricing power.
  • VEVYE high-deductible patient mix caused $8M Q1 2026 revenue hit; recurrence threatens guidance.
  • MELT-300 NDA submission H1 2027 faces 30% industry Phase 3 failure rate; delays H2 2028 launch.

What makes Harrow unique

  • Only national-scale FDA-registered compounding facility for sterile ophthalmic formulations.
  • Integrated model combines compounding, branded acquisitions, and biotech incubation in ophthalmology.
  • CEO Mark Baum's pharmacy background drives accessible pricing strategy versus traditional pharma.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Harrow who can refer or advise you

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-15%

1 year growth

-15%

2 year growth

-15%
Simply Wall St
Mar 26th, 2026
How Investors May Respond To Harrow (HROW) Issuing US$50M In 8.625% Senior Notes For Growth

Harrow, Inc. recently completed a private fixed‑income offering of US$50,000,000 in 8.625% senior unsecured notes due 2030, callable and guaranteed by its wholly owned domestic restricted subsidiaries, under Regulation S and Rule 144A. The additional 2030 notes give Harrow more financial flexibility to fund growth initiatives, product development, and future business development opportunities without issuing new equity. We’ll now examine how this US$50,000,000 senior unsecured notes issuance...

Yahoo Finance
Mar 3rd, 2026
Harrow misses Q4 earnings estimate by 34.5% despite revenue beat

Harrow reported fourth-quarter earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.40 per share, representing a 34.46% negative surprise. This compares to earnings of $0.25 per share in the same period last year. The pharmaceutical and drug compounding company posted revenues of $89.09 million for the quarter ended December 2025, slightly exceeding the Zacks Consensus Estimate by 0.33% and up from $66.83 million a year earlier. Over the last four quarters, Harrow has surpassed consensus earnings estimates twice and topped revenue estimates once. Harrow shares have gained 10.6% year-to-date, outperforming the S&P 500's 0.5% gain. However, unfavorable estimate revision trends have resulted in a Zacks Rank of 4 (Sell), suggesting potential near-term underperformance.

The Associated Press
Mar 2nd, 2026
Harrow posts record Q4 revenue of $89.1M, up 33%, guides 2026 revenue to $350M–$365M

Harrow, a North American ophthalmic disease management solutions provider, reported record fourth-quarter revenue of $89.1 million, up 33% year-over-year, and full-year 2025 revenue of $272.3 million, up 36% from 2024. The company posted GAAP net income of $6.6 million in Q4 but a full-year net loss of $5.1 million. Adjusted EBITDA reached $24.2 million in Q4 and $61.9 million for the full year. Harrow generated $43.9 million in operating cash flow for 2025, compared to $22.2 million used in operations in 2024. The company provided 2026 guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA. Harrow plans to double sales teams for key products and expand commercial operations whilst advancing its development pipeline.

Stock Titan
Nov 18th, 2025
Harrow Completes Melt Pharmaceuticals Acquisition

Harrow (Nasdaq: HROW) has completed its acquisition of Melt Pharmaceuticals, adding clinical-stage candidates MELT-210, MELT-300, and MELT-400. MELT-300, a sublingual midazolam and ketamine formulation, showed statistical superiority in Phase 2 and 3 trials. Harrow plans to submit an NDA in H1 2027, targeting approval in H1 2028 and commercial launch in H2 2028. Over 800 U.S. ophthalmic institutions currently use Harrow's MKO Melt product.

TipRanks
Sep 30th, 2025
Harrow Health Secures New $40 Million Credit Facility - TipRanks.com

Harrow Health ( ($HROW) ) just unveiled an update. On September 26, 2025, Harrow, Inc. entered into a New Credit Agreement with Fifth Third Bank for a senior secure...